Zoetis ZTS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Zoetis (ZTS) Business Model and Operations Summary
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Key Insights
Zoetis (ZTS) Core Market Data and Business Metrics
Latest Closing Price
$161.91Market Cap
$72.51 BillionPrice-Earnings Ratio
29.60Total Outstanding Shares
447.79 Million SharesTotal Employees
13,800Dividend
$0.50 Per Share QuarterlyIPO Date
February 1, 2013SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
10 Sylvan Way, Parsippany, NJ, 07054
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-2.66 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-315 Million |
| Net Cash Flow From Investing Activities | $-315 Million |
| Exchange Gains/Losses | $-32 Million |
| Net Cash Flow | $-54 Million |
| Net Cash Flow, Continuing | $-22 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Interest Expense, Operating | $225 Million |
| Nonoperating Income/Loss | $19 Million |
| Cost Of Revenue | $2.72 Billion |
| Basic Average Shares | $454.20 Million |
| Diluted Average Shares | $454.85 Million |
| Benefits Costs and Expenses | $6.12 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $2.38 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $10 Million |
| Comprehensive Income/Loss | $2.40 Billion |
| Other Comprehensive Income/Loss | $-101 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $6.05 Billion |
| Equity Attributable To Parent | $4.77 Billion |
| Current Assets | $5.99 Billion |
| Other Current Liabilities | $2.54 Billion |
| Noncurrent Assets | $8.25 Billion |
| Current Liabilities | $3.41 Billion |
Historical Dividends
Current dividend: $0.50 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Feb 6, 2025 | Jun 3, 2025 | Apr 21, 2025 | $0.5 | Quarterly |
| Dec 12, 2024 | Mar 4, 2025 | Jan 21, 2025 | $0.5 | Quarterly |
| Oct 10, 2024 | Dec 3, 2024 | Oct 31, 2024 | $0.432 | Quarterly |
| May 22, 2024 | Sep 4, 2024 | Jul 18, 2024 | $0.432 | Quarterly |
| Feb 6, 2024 | Jun 4, 2024 | Apr 19, 2024 | $0.432 | Quarterly |
| Dec 7, 2023 | Mar 1, 2024 | Jan 19, 2024 | $0.432 | Quarterly |